Insmed (INSM) Investor presentation summary

Strategic focus and therapeutic areas

• Pursues first- and best-in-class therapies in immunology, respiratory, inflammation, neuro, and rare diseases.

• Pipeline includes commercial, late-stage, and early-stage assets across multiple indications.

• Emphasizes operational excellence and evidence generation through global collaborations and real-world studies.

Financial performance and guidance

• Updated 2026 revenue guidance: $1.25B–$1.4B for brensocatib (BRINSUPRI), $450M–$470M for ARIKAYCE.

• Q2 2026 brensocatib revenue reached $309.2M, supporting raised full-year guidance.

• Peak revenue estimate for three lead assets raised to $14B+ across all indications.

Key products and clinical results

• BRINSUPRI approved for non-cystic fibrosis bronchiectasis (NCFB) in major markets, with flexible dosing and strong label claims.

• ARIKAYCE demonstrated significant improvements in respiratory symptoms and culture conversion in MACLD, with ongoing label expansion efforts.

• TPIP (treprostinil palmitil inhalation powder) showed strong efficacy and safety in PAH and PH-ILD, with once-daily dosing and broad Phase 3 program.